Johnson & Johnson's Erleada Cuts Cancer Spread Risk by 20%

Reuters reported on May 31 that Johnson & Johnson (NYSE:JNJ)'s prostate cancer drug Erleada showed positive results in a Phase 3 clinical trial. The drug, used with hormone therapy for six months before and after prostate surgery, reduced the risk of cancer spread or death by 20%.

The Product

Erleada (apalutamide) is an oral anti-androgen drug that targets androgen receptors. It is currently approved for non-metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer. The new results support its use in earlier-stage disease before and after surgery.

The Clinical Trial

The trial, conducted on patients with high-risk localized prostate cancer, showed that adding Erleada to standard hormone therapy improves the chances of eliminating cancer and reduces the risk of recurrence. Reuters did not disclose the sample size or additional statistical details.

Pricing and Availability

The price for this new indication has not been announced. Erleada is currently available by prescription in the US and other markets. The company is expected to file for FDA approval for expanded use.

Competition

Erleada faces competition from similar drugs such as Pfizer's Xtandi (enzalutamide) and Bayer's Nubeqa (darolutamide). However, its unique use before surgery may give it a competitive edge.

Potential Impact on the Company

The positive results are expected to boost Erleada sales, which reached $2.4 billion in 2025. The drug is part of JNJ's strong oncology portfolio, which also includes Darzalex and Imbruvica.